The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.
about
Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methodsVirtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.Levels of flurithromycin in female genital tissue.Treatment of typhoid fever with cefamandoleDelivering antibacterials to the lungs: considerations for optimizing outcomes.Single-dose antibiotic therapy: what has the past taught us?Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infectionsPharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similarTherapy of Rhodococcus equi disseminated infections in nude mice.Setting and revising antibacterial susceptibility breakpoints.Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.Evaluation of the BIOGRAM antimicrobial susceptibility test system.A novel method for determining the inhibitory potential of anti-HIV drugs.Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi modelEffect of inoculum size on bacteriolytic activity of cefminox and four other beta-lactam antibiotics against Escherichia coli.Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype.Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients.Correlation of in vitro activities of cephalothin and ceftazidime with their efficacies in the treatment of Staphylococcus aureus endocarditis in rabbits.Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir.The pharmacokinetics of new cephalosporins: significance in clinical practice.How the microbiology laboratory can improve antimicrobial therapy.Qualitative and quantitative drug-susceptibility tests in mycobacteriology.Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.The inhibitory quotient.Diffusion of isepamicin into cancellous and cortical bone tissue.A mechanistic theory to explain the efficacy of antiretroviral therapy.Pharmacokinetic parameters of ciprofloxacin (500 mg/5 mL) oral suspension in critically ill patients with severe bacterial pneumonia: a comparison of two dosages.Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis.Antibiotic-induced release of bacterial cell wall components in the pathogenesis of sepsis and septic shock: a review.Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa.Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime.Haemophilus influenzae infection of human respiratory mucosa in low concentrations of antibiotics.Promising new drugs in the treatment of tuberculosis and mycobacteriosis.
P2860
Q28362689-87D80CDF-03FE-4AA3-9F18-E25996E3B8AEQ34253139-12551120-F7A9-4864-B469-552A4478C4C1Q34720072-A544DA6E-B806-4758-B43D-7FF1B80FAA68Q35117884-9F501DC1-28CB-4A82-9027-29B85AC8EF8AQ35568488-73584161-6C75-4D98-9E00-BBF55B11DF8BQ35627814-2C9429F7-7C8D-45B5-96D8-0A79B9E71181Q35661686-B05065A1-7180-4BEF-A641-B03775C5DD18Q35814807-62562BF4-16F4-40B0-8133-5EB05F184CCEQ35820708-FCCF449C-E199-43FB-981D-118A89202F4FQ35822946-C53345D6-E127-4039-B833-7A16F77EFA89Q35862691-60318472-4578-4E57-BE0A-F95BE6499149Q35913176-C22B87F8-F001-4E80-BF59-7358F98AB8E0Q36870827-19C94DE5-49AD-44D8-94A2-C6CB417668E7Q37200076-6365546B-1360-41E9-8BA8-BE824E89256CQ37616810-60E7E7CD-49EA-48A4-9394-7BFEC7F9496BQ39558024-8C23FCCB-9A19-45D2-BAB3-B666EA3AE7CFQ39871085-40F26D40-3365-4667-BA08-094A20D2E52FQ39895301-8F2759DC-CC56-4232-A0D6-A3C13459EB90Q40131806-71565680-58FB-4F99-B7EF-D883CD30C12CQ40283340-E7F8A29C-50CA-46BF-9E91-14CC6370D0AFQ40621865-A9897533-A781-43E0-A2D0-9D9E81E835EEQ41269323-ACB6690F-EE02-4897-A2E0-BD276C65A388Q41843970-37661601-9330-4233-B2EF-7BCECF322EF9Q42140764-C53BA41E-ABDB-4921-B1D0-2567E817EE0CQ42210562-DFDCF4E0-208A-49D1-8F9B-3A11E9233712Q42408718-312A176C-45F1-486F-96B9-FCD4EF01BF73Q42671234-51040686-515A-4066-AF1B-9B5037FA5E64Q42687488-82C93381-DB21-42C8-B241-26F37EEF31E7Q43721565-776A763B-CF5B-4307-9DEF-FE510474D907Q43997734-75763204-658E-49D6-94FA-BB0D7998CA83Q44023516-1BFB3B00-392F-4B2B-9894-8E7C611238BEQ45137694-D7B3C627-2EAC-4C24-9777-5593767EBE18Q46814128-4BC13BF0-8A41-49EB-B084-BE0DA02659DEQ52374966-0F6B237E-65BD-41F5-873A-111A09F7E7CDQ52516220-216C24AF-6590-405F-979C-2336F55D4714Q54361410-3BE63D45-063B-4511-A59E-3674F87E105E
P2860
The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
1981年论文
@zh
1981年论文
@zh-cn
name
The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.
@ast
The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.
@en
type
label
The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.
@ast
The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.
@en
prefLabel
The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.
@ast
The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.
@en
P1476
The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.
@en
P2093
P304
P356
10.1001/JAMA.1981.03320140063033
P407
P577
1981-10-01T00:00:00Z